NRX Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax
NRX Pharmaceuticals, Inc. (NRXP) reported Other Comprehensive Income (Loss), Net of Tax of -$3.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2024-11-14
- NRX Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was -$3.00K.
- NRX Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was $0.00.
- NRX Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-12-31 was $30.18M.
- NRX Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $0.00.
- NRX Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $30.15M, a 24.15% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was $39.75M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$3.00K 10-Q · filed 2024-11-14 | -$3.00K derived: sum of 2 quarters · filed 2024-11-14 | -$3.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2023-12-31 | $30.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $30.18M derived: sum of 2 quarters · filed 2024-11-14 | $30.05M derived: sum of 3 quarters · filed 2024-11-14 | $30.15M 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | -$128.00K derived: sum of 2 quarters · filed 2024-11-14 | -$22.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$128.00K 10-Q · filed 2024-08-14 | -$22.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $106.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $39.75M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |